MedTrace Logo

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

NCT04439006 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-12-26

No results posted yet for this study

Summary

This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing.

Conditions

  • Aplastic Anemia
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
  • Monoclonal B-Cell Lymphocytosis
  • Monoclonal Gammopathy of Undetermined Significance
  • Myelodysplastic Syndrome
  • Symptomatic COVID-19 Infection Laboratory-Confirmed

Interventions

OTHER

Best Practice

Receive usual care

DRUG

Ibrutinib

Given PO

Sponsors & Collaborators

  • Janssen Scientific Affairs, LLC

    collaborator INDUSTRY

  • Jennifer Woyach

    lead OTHER

Principal Investigators

  • Jennifer A Woyach, MD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-23
Primary Completion
2022-09-20
Completion
2022-09-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04439006 on ClinicalTrials.gov